Atara Reports Initial Data for Multiple Sclerosis Candidate

Atara Biotherapeutics, Inc. ATRA announced initial ATA188 phase I safety results for patients with progressive multiple sclerosis (MS) at the 5th Congress of the European Academy of Neurology (EAN) in Oslo, Norway. The primary objective of the ongoing ATA188 phase I, dose-escalating clinical study is to evaluate safety and tolerability for patients with progressive MS.